Corporate Culture of Denial Results in Preventable Deaths Fri, 7 Jan 2005 Failure to disclose the hazardous effects of Vioxx and Prozac are evidence of a corporate culture that has run amok. Uncovered company documents – some obtained through litigation, others unearthed by whistleblowers – reveal that the manufacturers knew…
Doctors Without Borders: Why you can’t trust medical journals anymore Tue, 13 Apr 2004 Related link: Hear an interview with Shannon Brownlee on NPR at: http://www.npr.org/features/feature.php?wfId=1874563 Doctors Without Borders in the Washington Monthly (excerpt below), looks at the intricate web of collaborating players in medicine who are financially tied one…
Bush’s plan to screen for mental health meets opposition in Illinois – British Med J Fri, 5 Nov 2004 The New Freedom Commission recommendation calling for government screening the entire nation for mental illness, beginning with America’s 52 million children, is backfiring. The recommendation runs contrary to freely made health…
October 29, 2001 FYI Widely disparate perspectives are presented in an article in the Maryland Daily Record re: The Court of Appeals of Maryland decision (Gimes v Kennedy Krieger Institute, Aug 16, 2001). That 6-to-1 landmark decision severely criticized the practice of exposing healthy children to risks of harm in…
NIMH-Harvard study: 74% children prescribed SSRI suffer adverse effects Fri, 22 Aug 2003 A report in the Journal of Child and Adolescent Psychopharmacology (abstract below) Dr. Timothy Wilens, Dr. Joseph Biederman, et al, child psychiatrists at Harvard’s teaching hospital, Massachusetts General, found that 22% of children and adolescents who had…
http://hedwig.mgh.harvard.edu/ardsnet/faq.html#3 The individuals participating in the ARDS Network are listed below: Steering Committee Chair: Gordon Bernard, M.D., Vanderbilt University Clinical Coordinating Center: Massachusetts General Hospital: David Schoenfeld, Ph.D. B. Taylor Thompson, M.D. Nancy Ringwood, R.N., CCRA Cathryn Oldmixon, R.N. NHLBI Project Office: Andrea Harabin, Ph.D. Myron…
<spanstyle=’font-size:11.0pt;font-family:Arial’>FEDERALLY-FUNDED RELAPSE PRODUCING EXPERIMENTS in PSYCHIATRY: DRUG WASHOUT / CHEMICAL PROVOCATION<spanstyle=’font-size:11.0pt;font-family:Arial’> <spanstyle=’font-size:11.0pt;font-family:Arial’>A PARTIAL BIBLIOGRAPHY (Jan 2000) <spanstyle=’font-size:11.0pt;font-family:Arial’>By VERA HASSNER SHARAV Experiments such as those listed below have no diagnostic or therapeutic purpose: They are conducted often on disabled veterans to test speculative, unproven theories. National Institute of Mental Health:<spanstyle=’font-size:11.0pt;font-family:Arial’>…
FDA Smoke & Mirrors Musical Chairs Wed, 16 Feb 2005 Amidst widespread public criticism of the FDA’s role as facilitators in the marketing of lethal drugs that killed thousands of people, the Administration made several announcements incorporating terminology (such as: “we’re in an era of openness” “transparency”). But politically correct…
Is there hope for Psychiatry to make it as a profession? Tue, 14 Jun 2005 The New York Times reports: “Psychiatrists have been searching for more than a century for some biological marker for mental disease, to little avail.” Indeed, the latest embarassing controversy that perennially plagues the psychiatric establishment…
Lies & Broken Promises_Drug firm Websites Fail to Disclose Test Data Sun, 9 Jan 2005 One year after PhRMA’s publicized proclamation of its “commitment to transparency” The Boston Globe reviewed pharmaceutical company websites searching for disclosure of clinical trial data. The Globe found that this voluntary approach failed miserably: “Last…
An Open Letter to Officials of the National Institute of Mental Health Fri, 30 Apr 2004 ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org From: Vera Hassner Sharav, President David Cohen, Ph.D. Secretary The ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) To: Thomas Insell, MD,…
VIOXX WITHDRAWAL: FDA TO JOIN AUDIO CONFERENCE ON NOVEMBER 10 Mon, 8 Nov 2004 To hear from FDA Office of New Drugs Acting Director Sandra Kweder, MD, in an interactive discussion of what the withdrawal of the blockbuster drug means for the agencys drug safety programs, the COX-2 inhibitor class…
